HeartFlow

HeartFlow is a medical technology company focused on coronary artery disease (CAD). Its stated aim is to help clinicians detect, understand, and manage CAD with precision tools and data-driven insights, supporting patient-specific care pathways. The company describes its broader vision as making coronary care proactive and patient-centered, with earlier detection and more effective long-term management. The company’s platform works with coronary computed tomography angiography (CCTA). HeartFlow says its analysis turns a CCTA scan into a personalized, dynamic 3D model of the heart that assesses anatomy and physiology. Its offerings include Roadmap Analysis, which is described as supporting consistent reading of CCTA and early CAD detection, and FFR CT Analysis, which assesses blood flow in the coronary tree and helps determine the potential benefit of revascularization. The company also reports Plaque Analysis coverage for a majority of insured lives in the United States in 2026. HeartFlow presents its products to clinicians and healthcare institutions, emphasizing individualized treatment decisions and efficient care pathways. Its website reports use at more than 1,800 institutions, more than 750,000 patients treated, over 625 peer-reviewed publications, and coverage for 99.5% of U.S. lives for FFR CT Analysis. The company says it has employees across the United States, Europe, and Japan, and lists San Francisco, California, as its headquarters, alongside locations including Austin, London, and Tokyo. HeartFlow became a public company in 2025 and is listed on Nasdaq under the ticker HTFL, according to its company timeline. Its About Us page identifies John Farquhar as CEO. The company remains active and positions itself around AI-enabled coronary care and ongoing management of CAD.

HeartFlow describes its development as centered on applying artificial intelligence and data-driven analysis to coronary care. Its company materials say it has developed solutions ranging from AI-powered 3D modeling of the heart to insights intended to change how coronary artery disease is detected, understood, and managed. The supplied company information does not state a founding year or name a founder, so those details are not included here. A core element of the company’s approach is the use of coronary CT angiography (CCTA) as the basis for personalized analysis. HeartFlow says its platform transforms a CCTA scan into a dynamic 3D heart model that assesses anatomy and physiology. The company frames this as a way to provide clearer disease insights and help clinicians choose patient-specific treatment pathways. Its homepage presents HeartFlow One as a platform for managing CAD and identifies Roadmap Analysis and FFR CT Analysis as components of its offering. Roadmap Analysis is described as enabling consistent CCTA reading and early detection; FFR CT Analysis assesses blood flow and helps determine the benefit of revascularization. The company reports growth in clinical use and supporting evidence, including more than 750,000 patients treated, use at more than 1,800 institutions, and over 625 peer-reviewed publications. Its About Us page also reports that FFR CT Analysis covers 99.5% of U.S. lives. These figures are company-reported metrics. The careers page describes HeartFlow as a global company with employees across the United States, Europe, and Japan, and identifies San Francisco, California, as its headquarters. The company’s published timeline records several developments in 2025 and 2026. In 2025, HeartFlow became a public company on Nasdaq under ticker HTFL and launched the GAMEFILM Registry. The company also says it was named one of the world’s most innovative companies by Fast Company that year. In 2026, its timeline notes U.S. coverage of Plaque Analysis for a majority of insured lives, the CCTA database surpassing 200 million annotated images, and the launch of the NAVIGATE-PCI Registry. The supplied material also says the GAMEFILM Registry expanded to NBA, MLB, and NHL alumni. HeartFlow continues to describe its purpose as enabling proactive, personalized coronary care and long-term management of CAD.

• Became a public company

• GAMEFILM Registry launched

• Plaque Analysis coverage expanded

• CCTA database surpassed 200 million annotated images

• NAVIGATE-PCI Registry launched

• GAMEFILM Registry expanded

An AI-enabled medical technology company providing coronary imaging analysis and insights to support personalized diagnosis, treatment decisions, and long-term management of coronary artery disease.

• HeartFlow One

  A platform presented as supporting lifelong management of coronary artery disease by combining CCTA with HeartFlow analysis.

• Roadmap Analysis

  An analysis offering described as supporting consistent CCTA reading and early detection of coronary artery disease.

• FFR CT Analysis

  An analysis offering that assesses blood flow in the coronary tree and helps determine the benefit of revascularization.

• Plaque Analysis

  A HeartFlow offering referenced in the company’s 2026 timeline.

1. 1Heartflow - Decisive Coronary Careheartflow.com
2. 2About Usheartflow.com
3. 3Careersheartflow.com
4. 4Contact Usheartflow.com
5. 5HeartFlow (United States)wikidata.org